rF1V-1018

BIOLOGICAL2 trials

Sponsors

Dynavax Technologies Corporation

Conditions

PlaguePlague, PneumonicPrevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia PestisVaccine-Preventable Diseases

Phase 2

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

CompletedNCT05506969

Dynavax Technologies CorporationPlague, Plague, Pneumonic, Vaccine-Preventable Diseases

Start: 2022-08-09End: 2024-04-26Updated: 2025-07-29

Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age

RecruitingNCT07207408

Dynavax Technologies CorporationPrevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis

Start: 2025-09-11End: 2027-08-31Target: 148Updated: 2026-06-18